Cargando…
The prognostic value of YAP1 on clinical outcomes in human cancers
Background: As an important downstream factor in the Hippo pathway, yes-associated protein 1(YAP1) has been detected to be elevated in various cancers and demonstrated to play a role in tumor development. Therefore, we evaluated by a meta-analysis the prognostic value of YAP1 in cancer patients. Res...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814621/ https://www.ncbi.nlm.nih.gov/pubmed/31613226 http://dx.doi.org/10.18632/aging.102358 |
_version_ | 1783463024260022272 |
---|---|
author | Wu, Ying Hou, Yanshen Xu, Peng Deng, Yujiao Liu, Kang Wang, Meng Tian, Tian Dai, Cong Li, Na Hao, Qian Song, Dingli Zhou, Ling hui Dai, Zhijun |
author_facet | Wu, Ying Hou, Yanshen Xu, Peng Deng, Yujiao Liu, Kang Wang, Meng Tian, Tian Dai, Cong Li, Na Hao, Qian Song, Dingli Zhou, Ling hui Dai, Zhijun |
author_sort | Wu, Ying |
collection | PubMed |
description | Background: As an important downstream factor in the Hippo pathway, yes-associated protein 1(YAP1) has been detected to be elevated in various cancers and demonstrated to play a role in tumor development. Therefore, we evaluated by a meta-analysis the prognostic value of YAP1 in cancer patients. Results: Sixty-eight studies with 8631 patients were identified. The results indicated that YAP1 overexpression predicted unfavorable patient prognosis in studies with overall survival (OS) (HR=1.76, 95%CI: 1.50-2.06, p<0.001) and disease-free survival (DFS) (HR=1.39, 95%CI: 1.22-1.59, p<0.001), as well as in studies with recurrence-free survival (RFS) (HR=2.38, 95%CI: 1.73-3.27, p<0.001), and disease-specific survival (DSS) (HR=2.04, 95%CI: 1.55-2.70, p<0.001). Meanwhile, YAP1 overexpression was also observed to be significantly associated with worse OS in GEPIA (HR=1.2, p<0.001). Conclusions: Overexpression of YAP1 showed great association with poorer prognosis in patients with various cancers, particularly liver cancer. Therefore, YAP1 might be an important prognostic marker and a novel target of cancer therapy. Methods: We searched for potential publications in several online databases and retrieved relevant data. Overall and subgroup analyses were performed. Begg’s and Egger’s tests were used to assess publication bias. Online dataset GEPIA was used to generate the survival curves and verify the prognostic role of YAP1 in patients with tumors. |
format | Online Article Text |
id | pubmed-6814621 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Impact Journals |
record_format | MEDLINE/PubMed |
spelling | pubmed-68146212019-11-05 The prognostic value of YAP1 on clinical outcomes in human cancers Wu, Ying Hou, Yanshen Xu, Peng Deng, Yujiao Liu, Kang Wang, Meng Tian, Tian Dai, Cong Li, Na Hao, Qian Song, Dingli Zhou, Ling hui Dai, Zhijun Aging (Albany NY) Research Paper Background: As an important downstream factor in the Hippo pathway, yes-associated protein 1(YAP1) has been detected to be elevated in various cancers and demonstrated to play a role in tumor development. Therefore, we evaluated by a meta-analysis the prognostic value of YAP1 in cancer patients. Results: Sixty-eight studies with 8631 patients were identified. The results indicated that YAP1 overexpression predicted unfavorable patient prognosis in studies with overall survival (OS) (HR=1.76, 95%CI: 1.50-2.06, p<0.001) and disease-free survival (DFS) (HR=1.39, 95%CI: 1.22-1.59, p<0.001), as well as in studies with recurrence-free survival (RFS) (HR=2.38, 95%CI: 1.73-3.27, p<0.001), and disease-specific survival (DSS) (HR=2.04, 95%CI: 1.55-2.70, p<0.001). Meanwhile, YAP1 overexpression was also observed to be significantly associated with worse OS in GEPIA (HR=1.2, p<0.001). Conclusions: Overexpression of YAP1 showed great association with poorer prognosis in patients with various cancers, particularly liver cancer. Therefore, YAP1 might be an important prognostic marker and a novel target of cancer therapy. Methods: We searched for potential publications in several online databases and retrieved relevant data. Overall and subgroup analyses were performed. Begg’s and Egger’s tests were used to assess publication bias. Online dataset GEPIA was used to generate the survival curves and verify the prognostic role of YAP1 in patients with tumors. Impact Journals 2019-10-15 /pmc/articles/PMC6814621/ /pubmed/31613226 http://dx.doi.org/10.18632/aging.102358 Text en Copyright © 2019 Wu et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Wu, Ying Hou, Yanshen Xu, Peng Deng, Yujiao Liu, Kang Wang, Meng Tian, Tian Dai, Cong Li, Na Hao, Qian Song, Dingli Zhou, Ling hui Dai, Zhijun The prognostic value of YAP1 on clinical outcomes in human cancers |
title | The prognostic value of YAP1 on clinical outcomes in human cancers |
title_full | The prognostic value of YAP1 on clinical outcomes in human cancers |
title_fullStr | The prognostic value of YAP1 on clinical outcomes in human cancers |
title_full_unstemmed | The prognostic value of YAP1 on clinical outcomes in human cancers |
title_short | The prognostic value of YAP1 on clinical outcomes in human cancers |
title_sort | prognostic value of yap1 on clinical outcomes in human cancers |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814621/ https://www.ncbi.nlm.nih.gov/pubmed/31613226 http://dx.doi.org/10.18632/aging.102358 |
work_keys_str_mv | AT wuying theprognosticvalueofyap1onclinicaloutcomesinhumancancers AT houyanshen theprognosticvalueofyap1onclinicaloutcomesinhumancancers AT xupeng theprognosticvalueofyap1onclinicaloutcomesinhumancancers AT dengyujiao theprognosticvalueofyap1onclinicaloutcomesinhumancancers AT liukang theprognosticvalueofyap1onclinicaloutcomesinhumancancers AT wangmeng theprognosticvalueofyap1onclinicaloutcomesinhumancancers AT tiantian theprognosticvalueofyap1onclinicaloutcomesinhumancancers AT daicong theprognosticvalueofyap1onclinicaloutcomesinhumancancers AT lina theprognosticvalueofyap1onclinicaloutcomesinhumancancers AT haoqian theprognosticvalueofyap1onclinicaloutcomesinhumancancers AT songdingli theprognosticvalueofyap1onclinicaloutcomesinhumancancers AT zhoulinghui theprognosticvalueofyap1onclinicaloutcomesinhumancancers AT daizhijun theprognosticvalueofyap1onclinicaloutcomesinhumancancers AT wuying prognosticvalueofyap1onclinicaloutcomesinhumancancers AT houyanshen prognosticvalueofyap1onclinicaloutcomesinhumancancers AT xupeng prognosticvalueofyap1onclinicaloutcomesinhumancancers AT dengyujiao prognosticvalueofyap1onclinicaloutcomesinhumancancers AT liukang prognosticvalueofyap1onclinicaloutcomesinhumancancers AT wangmeng prognosticvalueofyap1onclinicaloutcomesinhumancancers AT tiantian prognosticvalueofyap1onclinicaloutcomesinhumancancers AT daicong prognosticvalueofyap1onclinicaloutcomesinhumancancers AT lina prognosticvalueofyap1onclinicaloutcomesinhumancancers AT haoqian prognosticvalueofyap1onclinicaloutcomesinhumancancers AT songdingli prognosticvalueofyap1onclinicaloutcomesinhumancancers AT zhoulinghui prognosticvalueofyap1onclinicaloutcomesinhumancancers AT daizhijun prognosticvalueofyap1onclinicaloutcomesinhumancancers |